title: Cost-effectiveness of one-time genetic testing to minimize lifetime adverse drug reactions.
abstract: We evaluated the cost-effectiveness of one-time pharmacogenomic testing for preventing adverse drug reactions (ADRs) over a patient's lifetime. We developed a Markov-based Monte Carlo microsimulation model to represent the ADR events in the lifetime of each patient. The base-case considered a 40-year-old patient. We measured health outcomes in life years (LYs) and quality-adjusted LYs (QALYs) and estimated costs using 2013 US$. In the base-case, one-time genetic testing had an incremental cost-effectiveness ratio (ICER) of $43,165 (95% confidence interval (CI) is ($42,769,$43,561)) per additional LY and $53,680 per additional QALY (95% CI is ($53,182,$54,179)), hence under the base-case one-time genetic testing is cost-effective. The ICER values were most sensitive to the average probability of death due to ADR, reduction in ADR rate due to genetic testing, mean ADR rate and cost of genetic testing.
authors.affiliation: Department of Industrial & Systems Engineering, University of Wisconsin-Madison, Madison, WI, USA.
authors.forename: O
authors.initials: O
authors.lastname: Alagoz
authors.affiliation: Department of Psychiatry, Sage Neuroscience Center, Albuquerque, NM, USA.
authors.forename: D
authors.initials: D
authors.lastname: Durham
authors.affiliation: Ally Clinical Diagnostics, Dallas, TX, USA.
authors.forename: K
authors.initials: K
authors.lastname: Kasirajan
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003362:Cost-Benefit Analysis; D064420:Drug-Related Side Effects and Adverse Reactions / Q000191:economics* / Q000235:genetics*; D005820:Genetic Testing / Q000191:economics*; D006801:Humans; D008390:Markov Chains; D008875:Middle Aged; D009010:Monte Carlo Method